Drug intelligence / Profile preview

XW4475

Development stage: Preclinical
Lead developer: Sciwind Biosciences
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

XW4475 is a novel, long-acting analog of urocortin 2 (UCN2) developed by Sciwind Biosciences. It is designed for improved potency and selectivity as a UCN2 analog. Preclinical studies in rodent models have shown that XW4475 has a favorable pharmacokinetic profile and demonstrates promising efficacy in reducing fat mass, preserving muscle mass, and improving overall body composition. The drug targets metabolic health and body composition, making it a potential candidate for the treatment of obesity or related metabolic diseases[2].

Targets

CRHR2 (Corticotropin-releasing hormone receptor 2)

Beyond the preview

Go deeper on XW4475.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XW4475.

Explore the full profile